NCT00461565 - FDA Phase IV - Commitment - Retinal Function Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2005

Study Completion Date

October 31, 2006

Conditions

Safety

Interventions

DRUG

Sildenafil

A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).

DRUG

Placebo

A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).

DRUG

Vardenafil (Levitra, BAY38-9456)

B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).

DRUG

Placebo

B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).